A phase 2 study evaluates the safety and efficacy of brentuximab vedotin and nivolumab plus chemotherapy in patients with early-stage classical Hodgkin lymphoma.

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

Could glandular fever lead to brain lymphoma? Specialists Dr Adolfo de la Fuente and Dr Agustín Penedo explain the ...

This week on "The Readout LOUD," a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

After researching lymphomas for more than a decade and beating the illness herself, NYU Langone professor and alum Lisa Roth ...

A retrospective review suggests that increasing radiation dose from 4 Gy to 8 Gy for indolent B-cell lymphomas is associated ...

The immune system is designed to protect us against viruses and bacteria. In autoimmune diseases, however, the immune system instead attacks the body's own cells. Conditions such as systemic lupus ...

Burkitt’s lymphoma owes its name to the Irish surgeon Denis P. Burkitt, who in 1958 described 38 Ugandan children with rapidly enlarging facial tumors that were uniformly fatal. 7 He postulated that ...